CellFE®, a disruptive life sciences company marketing non-viral, non-electroporative cell therapy manufacturing tools, today announced several strategic system placements with major pharmaceutical and ...

Researchers have developed lipid nanoparticles (LNPs) that cross the blood-brain barrier (BBB) and precisely target brain cells, a major step toward treating neurological diseases like Alzheimer’s.

However, our understanding of how gradual changes in gene dosage affect molecular, cellular, and organismal traits is currently limited. To address this gap, we induced gradual changes in gene ...

In this manuscript, Yao et al. present solid evidence to show that MnMYL3 may serve as a receptor for NNV via macropinocytosis. This manuscript is valuable for understanding the molecular mechanisms ...

This article explores some of the challenges in developing cell lines for therapeutics, such as cell line stability, and how ...

Median OS increased from 11 to 13 months in IMNN-001 treatment group based on latest data analysis No change in IMNN-001 favorable safety profile including no reports of serious immune-related adverse ...

MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of ...

You've got a lot to consider when searching for the best cell phone plan, whether it's what kind of coverage you can expect or what kind of perks come with your plan. But the main question I wind ...

The global flow cytometry market generated revenue of approximately USD 6.8 billion in 2023 and is projected to reach USD 16.5 billion by 2032, with a compound annual growth rate (CAGR) of 10.3% from ...

Natural killer (NK) cells play an important role in the innate immune response to cancer and viral infections, and their ...

A precancerous cell is a cell with certain abnormalities that makes it more likely to become cancerous. These abnormalities don't mean that it will become cancer—in fact, most don't—but the diagnosis ...